A real-world study of PSA changes and adverse effects of enzalutamide combined with ADT in the treatment of mHSPC

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500109370

Enrollment

Unknown

Registered

2025-09-17

Start date

2025-09-30

Completion date

Unknown

Last updated

2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

mHSPC group:None

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1.mHSPC patients confirmed by histopathological examination; 2.PSA>0.2ng/ml; 3.Measurable or evaluable lesions were present according to RECIST1.1 criteria; 4.Patients were fully aware of this study and voluntarily provided written informed consent; 5.The predicted survival was more than 12 months;

Exclusion criteria

Exclusion criteria: 1.PSA<0.2ng/ml; 2.Patients with endocrine or chemotherapy contraindications; 3.Patients with oral medication barriers; 4.Other conditions considered by the investigator to be ineligible;

Design outcomes

Primary

Measure	Time frame
Prostate specific antigen;	—

Secondary

Measure	Time frame
Adverse events;	—

Countries

China

Contacts

Public ContactYichun Zheng

The Fourth Affiliated Hospital, Zhejiang University School of Medicine

2101090@zju.edu.cn+86 137 5711 8232

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026